^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | LX-039 (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
399P - Results from a first-in-human phase Ia/b study of LX-039, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal patients with ER+, HER2- advanced breast cancer (ABC)
Published date:
10/16/2023
Excerpt:
Median PFS in the ITT population was 5.5months (95% CI: 3.5, 5.9). CBR at 24 weeks was 40.0% and DCR was 70.3%....LX-039 was well tolerated with preliminary anti-tumor activity in ER+, HER2- ABC.
Trial ID:
